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1 A1AT = alpha-1-antitrypsin; COPD = chronic obstructive pulmonary disease; IL = interleukin; LTB4 = leukotriene B4
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Introduction
The American Thoracic Society international conference
is the largest gathering of lung specialists in the world,
attended by over 15,000 people from 80 countries. The
meeting aims to offer the latest and most significant
developments in clinical practice, and clinical and basic
research to physicians, scientists and health care
workers. The program this year was made up of more
than 300 scientific and clinical symposia. In this report I
will concentrate on two important aspects relating to the
basic mechanisms of inflammation in lung disease,
namely leukocyte recruitment and alpha-1-antitrypsin
(A1AT) deficiency.
Review
Leukocyte adhesion and recruitment
Unique mechanisms of leukocyte migration from the blood-
stream to the lung have been proposed with regard to the
profile of the adhesion molecules, cytokines and chemokines
involved, providing potential targets for pharmacological
agents to control the inflammatory process. Data presented at
this conference provided further insight into the mechanisms
of leukocyte adhesion and recruitment into the lung and the
potential effects of therapeutic agents on this process.
There is accumulating evidence that the mechanisms
involved in leukocyte recruitment into the lung are depen-
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The program at this year’s American Thoracic Society international conference included over 300
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development of novel anti-inflammatory therapies for a variety of lung diseases.
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dent upon the stimulus and the site of migration. Data from
SJ Hislip (University College, Ireland) demonstrated that
the conversion from CD18-independent to CD18-depen-
dent leukotriene B4 (LTB4)-induced and IL8-induced
migration during acute inflammatory episodes may be due
to n-formyl methionyl leucyl phenylalanine priming [1]. This
effect was demonstrated using healthy neutrophils and
antibodies to the CD11/18 integrin complex. In addition U
Maus (Justus-Liebig-University, Germany) [2] reported that
monocyte recruitment to mouse alveoli was dependent
upon CD18, VLA-4 and intercellular adhesion molecule-1
under basal conditions, but following bacterial endotoxin
stimulation CD11a and vascular cell adhesion molecule-1
were also involved, indicating a switch of mechanism. As
well as bacterial endotoxin, cigarette smoke can also up-
regulate adhesion molecule expression in the lung tissue.
AJ Heires (University NE Medical Centre, USA) reported
that cigarette smoke extract was able to up-regulate the
expression of intercellular adhesion molecule-1 on human
airway epithelial cells [3]. This effect could be abrogated
by a C5a receptor antibody, implicating this molecule in
the pathological process. AR Sousa (Guy’s Hospital
London, UK) presented data suggesting that the mecha-
nisms controlling leukocyte influx also differed according
to airway level and disease phenotype [4]. This group
found that the expression of granulocyte/macrophage
colony stimulating factor in the large airways was signifi-
cantly higher in smokers compared to non-smokers, and in
chronic obstructive pulmonary disease (COPD) patients
with airflow obstruction compared to subjects with normal
lung function. No differences, however, were found in the
small airways.
Studies using airway secretions are now also providing
some insight to the contribution of the various cytokines
and chemoattractants to leukocyte recruitment into the
lungs of patients with chronic lung diseases such as
COPD. IS Woolhouse (Queen Elizabeth Hospital Birm-
ingham, UK) and KM Beeh (University Hospital Mainz,
Germany) demonstrated (using different methodologies)
that the contribution of LTB4 to the neutrophil chemo-
tactic activity of sputum in COPD was significantly
higher (30–50%) than that of IL-8 (16–30%) [5,6]. In
addition DK Nelson (University of Arizona, USA) et al.
were able to demonstrate that the increased chemotac-
tic activity in exhaled breath condensate from smokers
could be attenuated using an LTB4  antagonist [7].
Taking these data together it would appear that LTB4 is
a particularly important neutrophil chemoattractant in
smoking-induced lung disease.
In addition to the neutrophil, monocyte recruitment to the
lungs is also likely to be important in COPD. SL Traves
(National Heart and Lung Institute, London, UK) reported
that in patients with COPD the migration of monocytes to
growth-related protein α was significantly increased com-
pared to monocytes from healthy volunteers [8]. This
group also found that there were significantly higher levels
of monocyte chemoattractant protein-1 and growth-
related protein α in the sputum in COPD compared to
healthy volunteers and smokers. Interestingly, KM Beeh
(University Hospital Mainz, Germany) also found that
monocyte migration in sputum from patients with lung
cancer was increased, compared to smokers and healthy
controls [9]. This effect appeared to be mediated by the
CC chemokine, macrophage inflammatory protein-1α as
chemotactic activity could be suppressed with an anti-
macrophage inflammatory protein-1α antibody.
Finally three studies were presented showing how a
number of COPD therapies, both in current use and
potential agents for the future, may exert beneficial effects
through the suppression of leukocyte migration. J Bishara
(Southampton General Hospital, UK) studied the in vitro
effects of fluticasone and salmeterol [10] and M Mikami
(Tokyo Metropolitan Hiro-o General Hospital, Japan)
studied the mucoactive agent s-carboxymethyl cysteine
[11]. Both research groups were able to demonstrate sig-
nificantly reduced transendothelial migration when neu-
trophils were incubated with these agents.
MP Pruniaux (Pfizer Laboratories, Fresnes, France) exam-
ined the effect of a novel phosphodiesterase 4 inhibitor on
neutrophil numbers in bronchoalveolar lavage following
lipopolysaccharide inhalation in rats [12]. This group
found pre-treatment with this drug successfully inhibited
neutrophil recruitment to the lungs of these animals and
concluded that this therapeutic strategy may prove effica-
cious in the treatment of lung inflammation.
Alpha-1-antitrypsin deficiency
The early concept of the development of emphysema in
patients with A1AT deficiency was based on a simple
balance theory where the amount of neutrophil elastase
released in the lung exceeded the amount of A1AT
present. The net result was persistence of elastase activity
leading to accelerated lung destruction. However it is now
becoming clear that the pathogenic process is more
complex than first believed.
A number of studies presented at the conference high-
lighted the influence of free elastase on aspects of host
defences as well as connective tissue breakdown. T
Spencer (University of Florida College of Medicine, USA)
reported that alveolar macrophage function in patients with
A1AT deficiency, as measured by lipopolysaccharide-stim-
ulated IL-1β production, was significantly reduced com-
pared to controls [13]. This appears to be an
elastase-related effect given that IL-1β production was
inhibited in control macrophages incubated with concen-
trations of elastase similar to that seen in A1AT deficiency.
In addition, P Sivasothy (University of Cambridge, UK)c
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found that when A1AT was cleaved by free elastase in
cystic fibrosis, it was unable to bind to human neutrophil
defensin-1, a potent pro-inflammatory mediator released
with elastase from the neutrophil azurophil granule [14].
Free elastase may also influence leukocyte recruitment in
A1AT deficiency. IS Woolhouse (Queen Elizabeth Hospi-
tal Birmingham, UK) reported that the chemotactic activity
of sputum from patients with A1AT deficiency is increased
compared to matched control patients with COPD [5].
The major contribution to this chemotactic activity was
from LTB4, which has previously been shown to be pro-
duced by alveolar macrophages in response to free elas-
tase [15]. Other molecules present in bronchial secretions
may also be important in leukocyte recruitment. JS Parmar
(Addenbrookes Hospital, Cambridge, UK) examined the
pro-inflammatory properties of A1AT polymers, which can
be detected in the lungs of some patients with A1AT defi-
ciency [16]. He found that the polymers were able to
induce neutrophil chemotaxis as well as shape change
which may further compound the lung damage seen in
vivo. H Parfrey (Cambridge Institute for Medical Research,
UK) attempted to prevent this polymerisation by introduc-
ing mutations into an interhelical cavity on the surface of
A1AT, however these mutations were ineffective [17].
Although the tissue damage seen in A1AT deficiency is
thought to be predominantly neutrophil-mediated it is now
becoming clear that the other cells may be involved. N.
Kokturk (University of Florida College of Medicine, USA)
reported that, despite the presence of increased levels of
neutrophilic burden in bronchoalveolar fluid from subjects
with A1AT deficiency, bronchial biopsy neutrophil counts
were not raised [18]. This may be due to neutrophil migra-
tion into the airway lumen; however, M Hofer (University
Hospital Zurich, Switzerland) found no difference in either
intraluminal or intramural neutrophil counts in bronchiolar
specimens from patients with A1AT deficiency and end-
stage emphysema [19]. This group did, however, find sig-
nificantly higher numbers of lymphocytes in the
A1AT-deficient subjects, which may suggest a role for this
cell in the pathogenesis of the disease.
The pathological and biochemical processes have been
further studied in animal models of A1AT deficiency.
These models also provide an opportunity to study the
effects of A1AT augmentation therapy on these
processes. G Lungarella (Sienna University, Italy) reported
the pathological changes seen in the pallid mouse (which
has a partial genetic deficiency of A1AT) following chronic
cigarette exposure compared to room air exposed controls
[20]. In the smoking mice he found that the emphysema-
tous lesions were more severe and were associated with
cellular infiltration and proliferation. In a similar study, Y
Takubo (University of Utah, USA) compared the differ-
ences in smoke-induced emphysema between pallid and
wild type mice [21]. This group found that the two types of
mice developed different types of emphysema, with the
pallid mouse resembling human panlobular emphysema
and the wild type resembling human centrilobular emphy-
sema. A Guerassimov (McGill University, Montreal,
Canada) attempted to attenuate the smoking-induced
emphysema in pallid mice by gene transfer of human
A1AT [22]. There was no difference, however, in degree
of emphysema following intramuscular injection of the
human A1AT vector. Immunostaining of the vector-
injected muscle suggested this lack of effect may be due
to accumulation of the protein in the muscle.
Conclusion
The data presented at this conference highlight the con-
siderable advances that have been made into the under-
standing of the basic mechanisms of inflammation in lung
disease. We are now beginning to unravel the role of the
individual adhesion molecules and cytokines in leukocyte
recruitment into the lung with particular reference to the
site and stimulus for migration, as well as disease pheno-
type. In alpha-1-antitrypsin deficiency the complex mecha-
nisms of elastase-mediated lung destruction via effects on
host defences are becoming clearer. In both of these
areas this understanding should allow the development of
specific novel anti-inflammatory therapies for acute and
chronic lung diseases in the future.
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